Onyda Xr Patent Expiration

Onyda Xr is a drug owned by Tris Pharma Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2041. Details of Onyda Xr's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918689 Liquid clonidine extended release composition
Jul, 2041

(16 years from now)

Active
US8062667 Modified release formulations containing drug-ion exchange resin complexes
Mar, 2029

(4 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Onyda Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Onyda Xr's family patents as well as insights into ongoing legal events on those patents.

Onyda Xr's Family Patents

Onyda Xr has patent protection in a total of 14 countries. It has a significant patent presence in the US with 59.5% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Onyda Xr.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Onyda Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Onyda Xr Generic API suppliers:

Clonidine Hydrochloride is the generic name for the brand Onyda Xr. 35 different companies have already filed for the generic of Onyda Xr, with Actavis Elizabeth having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Onyda Xr's generic

Alternative Brands for Onyda Xr

There are several other brand drugs using the same active ingredient (Clonidine Hydrochloride) as Onyda Xr. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Concordia Pharms Inc
Jenloga
Kapvay


Apart from brand drugs containing the same ingredient, some generics have also been filed for Clonidine Hydrochloride, Onyda Xr's active ingredient. Check the complete list of approved generic manufacturers for Onyda Xr





About Onyda Xr

Onyda Xr is a drug owned by Tris Pharma Inc. Onyda Xr uses Clonidine Hydrochloride as an active ingredient. Onyda Xr was launched by Tris Pharma Inc in 2024.

Approval Date:

Onyda Xr was approved by FDA for market use on 24 May, 2024.

Active Ingredient:

Onyda Xr uses Clonidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Clonidine Hydrochloride ingredient

Dosage:

Onyda Xr is available in suspension, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.1MG/ML SUSPENSION, EXTENDED RELEASE Prescription ORAL